Seroepidemiologic study on convalescent sera from dengue fever patients in Jinghong, Yunnan

Yingshuo Ma; Man Li; Lyu Xie; Na Gao; Dongying Fan; Kaihao Feng; Yao Yao; Yong Zhou; Ziyang Sheng; Hongning Zhou; Hui Chen; Jing An

doi:10.1016/j.virs.2021.12.001

February 2022

Citation: Yingshuo Ma, Man Li, Lyu Xie, Na Gao, Dongying Fan, Kaihao Feng, Yao Yao, Yong Zhou, Ziyang Sheng, Hongning Zhou, Hui Chen, Jing An. Seroepidemiologic study on convalescent sera from dengue fever patients in Jinghong, Yunnan .VIROLOGICA SINICA, 2022, 37(1) : 19-29. http://dx.doi.org/10.1016/j.virs.2021.12.001

Seroepidemiologic study on convalescent sera from dengue fever patients in Jinghong, Yunnan

Yingshuo Ma ^a ,
Man Li ^b ,
Lyu Xie ^b ,
Na Gao ^a ,
Dongying Fan ^a ,
Kaihao Feng ^a ,
Yao Yao ^c ,
Yong Zhou ^d ,
Ziyang Sheng ^a ,
Hongning Zhou ^{b,e
,,} ,
Hui Chen ^{a,f
,,} ,
Jing An ^{a
,,}

a Department of Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China
b Yunnan Institute of Parasitic Diseases, Pu’er, 665000, China
c People’s Hospital of Xishuangbanna Dai Autonomous Prefecture, Xishuangbanna, 666100, China
d Xishuangbanna Mental Health Center, Xishuangbanna, 666100, China
e Yunnan Provincial Key Laboratory of Vector-Borne Diseases Control and Research and Yunnan Provincial Collaborative Innovation Center for Public Health and Disease Prevention and Control (YPCICPHDPC), Pu’er, 665000, China
f Experimental Center for Basic Medical Teaching, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China

Corresponding author: Hongning Zhou, zhouhn66@163.com
Hui Chen, chenhuicxh@ccmu.edu.cn
Jing An, anjing@ccmu.edu.cn
Received Date: 29 April 2021
Accepted Date: 28 August 2021
Available online: 17 December 2021

Abstract

After dengue virus (DENV) infection, antibody-dependent enhancement (ADE) is easy to occur when the neutralizing antibody (NAb) gradually decreases to a sub-neutralizing concentration. In this cohort surveillance, we utilized sera samples collected from dengue fever patients at different convalescent phases in Jinghong City, to investigate the dynamic change rule of DENV-specific antibodies, and to analyze the risk of ADE caused by secondary infection with heterologous serotypes DENVs. For baseline serosurvey, 191 four-year and 99 six-year sera samples during convalescence were collected in 2017 and 2019, respectively. The positive rate of DENV-specific immunoglobulin G was 98.4% in 2017, which significantly decreased to 82.8% in 2019. The geometric mean titer (GMT) of NAb decreased from 1:155.35 to 1:46.66. Among 290 overall samples, 73 paired consecutive samples were used for follow-up serosurvey. In four-year sera, the GMTs of NAb against DENV-3 and cross-reactive antibodies against DENV-1, DENV-2 and DENV-4 were 1:167.70, 1:13.80, 1:18.54 and 1:45.26, respectively, which decreased to 1:53.18, 1:10.30, 1:14.60 and 1:8.17 in six-year sera. In age-stratified analysis, due to the increasing number of ADE positive samples from 2017 to 2019 in 31–40 and 51–60 years groups, the risk of ADE in DENV-4 infection was positively associated with the extension of convalescent phase, and the odd ratio was higher than other groups. With the recovery period lengthened, the risk of secondary infection with DENV-1 and DENV-2 was reduced. Our results offer essential experimental data for risk prediction of severe dengue in hyper-endemic dengue areas, and provide crucial scientific insight for the development of effective dengue vaccines.
- Dengue virus (DENV)
- , Seroepidemiology
- , Neutralizing antibody (NAb)
- , Cross-reactive antibody
- , Antibody dependent enhancement (ADE)

Electronic Supplementary Material

10.1016j.virs.2021.12.001-ESM.docx
References
1. Aguas R, Dorigatti I, Coudeville L, Luxemburger C, Ferguson NM. Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam. Sci Rep. 2019;9:9395.
2. Cedillo-Barron L, Garcia-Cordero J, Bustos-Arriaga J, Leon-Juarez M, Gutierrez-Castaneda B. Antibody response to dengue virus. Microbes Infect. 2014;16:711-720.
3. Clapham H, Cummings DA, Nisalak A, Kalayanarooj S, Thaisomboonsuk B, Klungthong C, Fernandez S, Srikiatkhachorn A, Macareo LR, Lessler J, Reiser J, Yoon IK. Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics. PLoS Negl Trop Dis. 2015;9:e0004262.
4. Clapham HE, Rodriguez-Barraquer I, Azman AS, Althouse BM, Salje H, Gibbons RV, Rothman AL, Jarman RG, Nisalak A, Thaisomboonsuk B, Kalayanarooj S, Nimmannitya S, Vaughn DW, Green S, Yoon IK, Cummings DA. Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection. J Infect Dis. 2016;213:1428-1435.
5. Coffey LL, Mertens E, Brehin AC, Fernandez-Garcia MD, Amara A, Despres P, Sakuntabhai A. Human genetic determinants of dengue virus susceptibility. Microbes Infect. 2009;11:143-156.
6. Cummings DA, Schwartz IB, Billings L, Shaw LB, Burke DS. Dynamic effects of antibody-dependent enhancement on the fitness of viruses. Proc Natl Acad Sci U S A. 2005;102:15259-15264.
7. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, Yoon IK, Jarman RG, Green S, Rothman AL, Cummings DA. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis. 2010;4:e617.
8. Gibbons RV, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, Endy TP, Mammen MP Jr, Srikiatkhachorn A. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg. 2007;77:910-913.
9. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A. 2007;104:9422-9427.
10. Guo X, Yang H, Wu C, Jiang J, Fan J, Li H, Zhu J, Yang Z, Li Y, Zhou H, Zhang J. Molecular Characterization and Viral Origin of the First Dengue Outbreak in Xishuangbanna, Yunnan Province, China, 2013. Am J Trop Med Hyg. 2015;93:390-393.
11. Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, Yoksan S, Luxemburger C, Lang J. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine. 2004;22:3563-3574.
12. Guy B, Lang J, Saville M, Jackson N. Vaccination Against Dengue: Challenges and Current Developments. Annu Rev Med. 2016;67:387-404.
13. Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S, Morier L, Alvarez A, Gould EA, Kouri G, Halstead SB. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis. 2007;13:282-286.
14. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg. 19901;42:179–184.
15. Halstead S. Recent advances in understanding dengue. F1000Research. 2019;8:1279.
16. Halstead SB. Dengue. Lancet. 2007;370:1644-1652.
17. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med. 1970;42:311-328.
18. Imrie A, Meeks J, Gurary A, Sukhbaatar M, Truong TT, Cropp CB, Effler P. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol. 2007;20:672-675.
19. Jiang L, Ma D, Ye C, Li L, Li X, Yang J, Zhao Y, Xi J, Wang X, Chen J, Pan Y, Shan X, Sun Q. Molecular Characterization of Dengue Virus Serotype 2 Cosmospolitan Genotype From 2015 Dengue Outbreak in Yunnan, China. Front Cell Infect Microbiol. 2018;8:219.
20. Khandia R, Munjal A, Dhama K, Karthik K, Tiwari R, Malik YS, Singh RK, Chaicumpa W. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. Front Immunol. 2018;9:597.
21. Li L, Li Y, Lu S, Dong J, Xu H, Zhang Q, Weng R, Yin Y, He R, Fang P, Shi H, Yu Y, Wu J, Liu Z, Hess JR. Epidemiological survey and screening strategy for dengue virus in blood donors from Yunnan Province. BMC Infect Dis. 2021;21:104.
22. Lin H, Wang X, Li Z, Li K, Lin C, Yang H, Yang W, Ye X. Epidemiological characteristics of dengue in mainland China from 1990 to 2019: A descriptive analysis. Medicine (Baltimore). 2020;99:e21982.
23. Lin RJ, Lee TH, Leo YS. Dengue in the elderly: a review. Expert Rev Anti Infect Ther. 2017;15:729-735.
24. Lin Y, Ma D, Wen S, Zeng F, Hong S, Li L, Li X, Wang X, Ma Z, Pan Y, Chen J, Xi J, Qiu L, Shan X, Sun Q. Molecular characterization of the viral structural gene of the first dengue virus type 1 outbreak in Xishuangbanna: A border area of China, Burma and Laos. Int J Infect Dis. 2019;79:152-161.
25. Luo S, Cui W, Li C, Ling F, Fu T, Liu Q, Ren J, Sun J. Seroprevalence of dengue IgG antibodies in symptomatic and asymptomatic individuals three years after an outbreak in Zhejiang Province, China. BMC Infect Dis. 2018;18:92.
26. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, Kuan G, Gordon A, Balmaseda A, Harris E. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7:e2357.
27. Narayan R, Tripathi S. Intrinsic ADE: The Dark Side of Antibody Dependent Enhancement During Dengue Infection. Front Cell Infect Microbiol. 2020;10:580096.
28. Ngwe Tun MM, Muta Y, Inoue S, Morita K. Persistence of Neutralizing Antibody Against Dengue Virus 2 After 70 Years from Infection in Nagasaki. Biores Open Access. 2016;5:188-191.
29. Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, Kochel TJ, Scott TW, Stoddard ST. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis. 2013;208:1026-1033.
30. Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat Q. 1997;50:161-169.
31. Reese JP, Stiasny-Kolster K, Oertel WH, Dodel RC. Health-related quality of life and economic burden in patients with restless legs syndrome. Expert Rev Pharmacoecon Outcomes Res. 2007;7:503-521.
32. Sang S, Liu-Helmersson J, Quam MBM, Zhou H, Guo X, Wu H, Liu Q. The evolutionary dynamics of DENV 4 genotype I over a 60-year period. PLoS Negl Trop Dis. 2019;13:e0007592.
33. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol. 1984;120:653-669.
34. Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15:745-759.
35. Simmons CP, Farrar JJ, Nguyen v V, Wills B. Dengue. N Engl J Med. 2012;366:1423-1432.
36. St John AL, Rathore APS. Adaptive immune responses to primary and secondary dengue virus infections. Nat Rev Immunol. 2019;19:218-230.
37. Tan JW, Wan Zahidi NF, Kow ASF, Soo KM, Shaari K, Israf DA, Chee HY, Tham CL. Mast cell stabilizing effect of a geranyl acetophenone in dengue virus infection using in vitro model of DENV3-induced RBL-2H3 cells. Biosci Rep. 2019;39:BSR20181273.
38. Tavano B, Boasso A. Effect of immunoglobin-like transcript 7 cross-linking on plasmacytoid dendritic cells differentiation into antigen-presenting cells. PLoS One. 2014;9:e89414.
39. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. Am J Trop Med Hyg. 2009;81:825-833.
40. van Panhuis WG, Gibbons RV, Endy TP, Rothman AL, Srikiatkhachorn A, Nisalak A, Burke DS, Cummings DA. Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers. J Infect Dis. 2010;202:1002-1010.
41. Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses. 2011;3:2374-2395.
42. Wang X, Ma D, Huang X, Li L, Li D, Zhao Y, Qiu L, Pan Y, Chen J, Xi J, Shan X, Sun Q. Complete genome analysis of dengue virus type 3 isolated from the 2013 dengue outbreak in Yunnan, China. Virus Res. 2017;238:164-170.
43. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. In: Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. Geneva: World Health Organization. 2009.
44. Wu JY, Lun ZR, James AA, Chen XG. Dengue Fever in mainland China. Am J Trop Med Hyg. 2010;83:664-671.
45. Zhang FC, Zhao H, Li LH, Jiang T, Hong WX, Wang J, Zhao LZ, Yang HQ, Ma DH, Bai CH, Shan XY, Deng YQ, Qin CF. Severe dengue outbreak in Yunnan, China, 2013. Int J Infect Dis. 2014;27:4-6.
46. Zhao Y, Li L, Ma D, Luo J, Ma Z, Wang X, Pan Y, Chen J, Xi J, Yang J, Qiu L, Bai C, Jiang L, Shan X, Sun Q. Molecular Characterization and Viral Origin of the 2015 Dengue Outbreak in Xishuangbanna, Yunnan, China. Sci Rep. 2016;6:34444.
47. Zhang HL, Fu SH, Deng Z, Yuan J, Jiang HY, Li MH, Gao XY, Wang JL, Liu YH, Yin ZL, Yang WH, Zhang YZ, Feng Y, Wang HY, Liang GD. An outbreak of imported dengue fever from Myanmar to the border of China, with its viral molecular epidemiological features. Zhonghua Liu Xing Bing Xue Za Zhi. 2013;34:428-432 (in Chinese)
Proportional views